via NIH
American and European researchers publish study in Nature Medicine reporting a new, single treatment option for cystic fibrosis patients
Researchers from the George Washington University (GW), the University of Perugia, and the University of Rome have discovered a potential new drug to treat and stop the progression of cystic fibrosis. Thymosin ?1 (T?1) is a novel therapeutic single molecule-based therapy that not only corrects genetic and tissue defects, but also significantly reduces inflammation seen in cystic fibrosis patients.
“Right now there are multiple treatments for cystic fibrosis, and while these have improved life expectancy dramatically, there is still only a lifespan of about 40 years for patients. No one treatment can stand alone,” said Allan L. Goldstein, Ph.D., co-author of the paper and Professor Emeritus in Residence of Biochemistry and Molecular Medicine at the GW School of Medicine and Health Sciences. “We developed a single treatment that can potentially correct the genetic defect that causes cystic fibrosis and decrease the inflammation that happens as a result.”
Cystic fibrosis is a genetic disease that causes persistent lung infections and limits the ability to breathe over time, and it affects approximately 70,000 worldwide and 30,000 in the U.S. alone. Cystic fibrosis is the result of mutations in the gene encoding the protein called the cystic fibrosis transmembrane conductance regulator (CFTR), which is important to maintain chloride-channel activity affecting the salt and water balance in the lungs. This mutation results in a misfolded CFTR protein, and its premature degradation leads to impaired chloride permeability and persistent lung inflammation.
Goldstein and co-authors Luigina Romani, Ph.D., M.D., at the University of Perugia and Enrico Garaci, M.D., at the University of Rome “San Raffaele,” both in Italy, published their results in Nature Medicine. They report that T?1, a synthetic version of a naturally occurring peptide first isolated from the thymus, corrects the multiple tissue defects found in the lungs and small intestines in a mouse model of cystic fibrosis, as well as the defects in the CFTR seen in cells isolated from cystic fibrosis patients. T?1 not only significantly reduces the inflammation seen in cystic fibrosis, but also increases CFTR maturation, stability, and activity. Due to this two-pronged action, T?1 offers a strong potential to be a single-molecule therapeutic agent to treat and stop the progression of cystic fibrosis.
Goldstein and colleagues first isolated and characterized T?1 as a biological response modifier with potent immune therapeutic activity in 1979. This research was done in large part at GW. Although the peptide is produced in small amounts in several peripheral lymphoid and non-lymphoid tissues, the highest concentrations of T?1 are found in the thymus. T?1, whose commercial name is Zadaxin, has been approved for clinical use for over 15 years in 35 countries in the treatment of patients with viral infections, immunodeficiency diseases, malignancies, and HIV/AIDS. Though not currently available in the U.S., it has an excellent safety profile and does not induce the side effects and toxicities commonly associated with most immunomodulatory agents.
Learn more: Research Uncovers Potential New Treatment to Treat and Stop Progression of Cystic Fibrosis
[osd_subscribe categories=’cystic-fibrosis’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “CYSTIC FIBROSIS”‘]
The Latest on: Cystic fibrosis
via Google News
The Latest on: Cystic fibrosis
- Krystal Biotech Announces FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trialon August 1, 2022 at 3:43 pm
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that the United States Food and Drug Administration (FDA) has accepted its Investigational ...
- Using iPSCs, BU researchers create cells that represent the airways of cystic fibrosis patientson August 1, 2022 at 9:00 am
Cystic fibrosis (CF) is caused by a mutation of the CFTR gene. While there are many hundreds of known mutations, not all of them are currently treatable which means a significant number of CF patients ...
- Krystal Biotech Receives FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trialon August 1, 2022 at 4:03 am
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that the United States Food and Drug Administration (FDA) has accepted its Investigational ...
- Former Detroit radio voice takes cystic fibrosis fight to Egypton July 28, 2022 at 7:35 pm
Laura Bonnell, long-time reporter at WWJ and WJR, brings expertise gained from her daughters' struggles to North Africa.
- Study finds disparities in first evaluation of infants with cystic fibrosis from minoritized groupson July 27, 2022 at 8:04 pm
Infants from minoritized racial and ethnic backgrounds who have positive newborn screening tests for cystic fibrosis received their diagnostic follow-up for the disease later than recommended and ...
- Study finds delays in initial cystic fibrosis evaluation in infants of coloron July 27, 2022 at 1:26 pm
Infants from minoritized racial and ethnic backgrounds who have positive newborn screening tests for cystic fibrosis received their diagnostic follow-up for the disease later than recommended and ...
- Study finds delays in initial cystic fibrosis evaluation in infants of coloron July 27, 2022 at 1:09 pm
Newborn screening results for cystic fibrosis are generally sent to primary care offices that refer infants with out-of-range tests to facilities with expertise in diagnostic testing and treatment.
- People with Cystic Fibrosis encouraged to ‘Live Fearlessly’on July 26, 2022 at 9:45 am
That art turned into a show -- which became a success -- and is now a non-profit organiztion used to encourage kids like Boston, who also lives with Cystic Fibrosis to "Live Fearlessly".
- Cystic Fibrosis Foundation Announces 2022 Impact Grant Recipientson July 26, 2022 at 7:00 am
The Cystic Fibrosis Foundation today announced the recipients of its seventh annual Impact Grants, a program which provides up to $10,000 in funding per year for up to two years to individuals and ...
via Bing News